News

Authorities in Chile have approved Orladeyo (berotralstat) to prevent swelling attacks in hereditary angioedema (HAE) patients 12 and older, marking the therapy’s first marketing authorization in a Latin American country. The preventive, or prophylactic, oral therapy from BioCryst Pharmaceuticals holds similar approvals in the U.S.,…

Nearly half of hereditary angioedema (HAE) patients in the U.K. are on long-term prophylactic treatment to prevent swelling attacks, with more than 80% keeping a supply of on-demand therapies at home to treat sudden flares. That’s according to data from a new national survey that also provided information on…

A 48-year-old man experienced complete remission from hereditary angioedema (HAE) after undergoing a bone marrow transplant for blood cancer, a case study reports. The transplanted stem cells might have given rise to new cells that acted as a healthy source of C1-inhibitor (C1-INH), the protein that is missing or…

An elderly woman developed angioedema about 20 days after being given ticagrelor, a medicine that prevents blood clots from forming and is commonly used to lower the risk of a heart attack or stroke. “Given the uncommon number of cases reported involving ticagrelor-induced angioedema and the even rarer, delayed…

Hereditary angioedema (HAE) Awareness Day is an annual global event held each May 16 to call attention to the disease, which is estimated to affect 1 in 50,000 to 150,000 people worldwide. The day focuses on activities that unite the HAE community and raise awareness among the general…

An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the Phase 2 portion of a clinical trial, according to its developer, Intellia Therapeutics. “We are pleased to announce dosing has begun in the Phase 2 study of NTLA-2002,”…

A pregnant woman with type 3 hereditary angioedema (HAE) had potential swelling attacks effectively controlled during both pregnancy and breastfeeding with the use of subcutaneous or under-the-skin injections of a plasma-derived C1 esterase inhibitor (C1-INH), according to a case report from Spain. Researchers say this may be the first…

Preventive treatment with Orladeyo (berotralstat) for up to two years led to prolonged periods of no swelling attacks in people with hereditary angioedema (HAE), irrespective of age, gender, or prior preventive treatments, according to a post-hoc analysis of the Phase 2/3 APeX-S trial. “These data demonstrate how our…

A 48-year-old man developed angioedema after taking losartan, a medication commonly used to treat high blood pressure, a U.S. case study reported. Losartan, sold under the brand name Cozaar, is used to manage cardiovascular conditions, including lowering the risk of stroke with heart disease. To date, 20 reports have…

Insurance issues significantly affected the physical, psychological, and financial health of people with hereditary angioedema (HAE) in the U.S., according to a recent patient survey. Patients reported that health insurance delays and coverage denials led to more frequent HAE attacks, urgent care visits, missed work or school, and greater…